“The TIME Magazine 100 List for Healthcare? That’s cool & all, and I’m happy for Tom Powles, but I personally have always been after this shiny piece of metal …”

Behold — the Uromigos cup.

#UromigosLive24
#TeamLA : Tanya Dorff Petros Grivas
Uromigos.org

In Annals of Oncology, results of translational analyses studying the predictive and prognostic values of molecular subtypes & genomic alterations 🧬 in the MITO END-3 trial investigating the addition of Avelumab to chemo in metastatic endometrial cancer

annalsofoncology.org/article/S0923-…

Just in JAMA Network Open 👉Our paper on treatment trends and attrition rates for advanced #bladdercancer in the US👉2/3rd of patients did not receive even 2nd-line Rx. Grateful for mentorship by Umang Swami Neeraj Agarwal, MD, FASCO. Link👉 bit.ly/3UHwBgv GU Cancer Research Program @HuntsmanCancer OncoAlert

We are so excited to have the @uromigos back for kidney cancer board review & 2024 updates

First up with Localized RCC discussing risk factors, who needs genetic testing, who qualifies for adjuvant therapy…& who’s a faster swimmer btw Brian Rini, MD & Tom Powles

Silke Gillessen summaries the #APCCC meeting in Lugano on our most recent podcast podcasters.spotify.com/pod/show/the-u…

Which team will win the highly coveted Uromigos #UromigosCup competition to be invited to the #UromigosLive2024 meeting?
👇👇
Sumanta K. Pal, MD, FASCO Petros Grivas Tanya Dorff Neeraj Agarwal, MD, FASCO Toni Choueiri, MD Tian Zhang, MD, MHS

“So I’m backstage with Taylor, and Travis comes up to me and is like - ‘How does it feel to win the Uromigos cup?’”

#UromigosLive24 #SuperbowlOfOncology
#TeamLA : Tanya Dorff Petros Grivas

It has been a fantastic Advanced Prostate Cancer Consensus Conference meeting. Already looking forward to APCCC 2026!

Biomarker data from adjuvant ipi/nivo vs placebo study in renal cancer shows circulating Kidney injury marker-1(KIM-1), which is over expressed & prognostic in RCC #AACR24 , maybe important (along with PD-L1) in response to ipi/nivo. Patient selection for adjuvant IO is important

Check out our APCCC podcasts with Jason Efstathiou and Piet Ost discuss the data for and against adjuvant radiotherapy. podcasters.spotify.com/pod/show/the-u…

APCCC debate with Thomas Zilli and Pierre Blanchard covering radiation therapy for metastatic disease from Lugano. Thanks to Neeraj Agarwal, MD, FASCO for help with the tweet. #APCCC2024 OncoAlert . t.ly/D7N0_

Thrilled...Delighted and Starstruck⭐️
What an honor and a delight to record with these amazing Four colleagues:
Declan Murphy🇦🇺
Renu Eapen 🇦🇺
Brian Rini, MD 🇺🇸
Tom Powles 🇺🇸
OncoAlert 🚨Could not be prouder of this GU Cast | Urology podcast! and Uromigos collaboration...Stay tuned

A +ve CHMP opinion for gem/cis + nivolumab (CheckMate -901 trial) today Michiel van der Heijden Matt Galsky #APCCC24 Likely to result in EMA approval. This will compete with maintenance avelumab due to ⬆️ RR & CR rate, but EV/pembro will follow soon I hope . news.bms.com/news/corporate…

🚨 New Paper Alert! 🚨 Nivolumab plus Cabozantinib Maintains Long-Term Survival Benefit in Advanced Renal Cell Carcinoma

oncodaily.com/55697.html

ESMO Open Tom Powles Andrea Apolo, M.D. Toni Choueiri, MD Maite Bourlon Mauricio Burotto Howard Gurney Elizabeth R Kessler @myesmo Yoshihiko Tomita…

Looking for teams for #uromigoslive24 to take on the team from LA. Hard it beat Tanya, Monty and Petros…..

Brian Rini, MD Uromigos Tom Powles Nazli Dizman Toni Choueiri, MD Neeraj Agarwal, MD, FASCO 💙alison birtle Petros Grivas Rana McKay Tanya Dorff Matt Galsky “Maybe.”

Just out on ESMO Open
By our OncoAlert 🚨GU faculty Tom Powles Andrea Apolo, M.D. Toni Choueiri, MD and Team

Extended Follow Up from CheckMate 9ER

Report provides updated efficacy and safety data on Nivolumab plus Cabozantinib (NIVO + CABO) 🆚 sunitinib (SUN) for 1⃣st line treatment…

Just out in ESMO open ESMO - Eur. Oncology With 44.0 months of median follow-up nivolumab/cabozantinib continues to outperform sunitinib in M1 clear cell RCC. The 3 VEGF/TKI combinations have more similarities than differences and track each other with longer follow up gbr01.safelinks.protection.outlook.com/?url=https%3A%…

Singapore Translational Cancer Consortium & Mount Sinai Hospital joining the IMCORE cancer research collaboration of 27 cancer centres & Roche. 96 cancer research project with >2000 scientists/HCPs and many high impact publications.Asian expansion reflects the global network

The anti–programmed death 1 antibody pembrolizumab was approved by the U.S. FDA as adjuvant therapy after surgery for renal-cell carcinoma on the basis of improvements in disease-free survival observed in KEYNOTE-564. Data on overall survival are needed. nej.md/3TVLuKz